2022 - Research.com Best Scientist Award
The scientist’s investigation covers issues in Internal medicine, Leukemia, Chronic lymphocytic leukemia, Gastroenterology and Immunology. His Internal medicine research incorporates elements of Surgery and Oncology. His studies in Leukemia integrate themes in fields like Survival rate, Myeloid leukemia, Pharmacology and Lymphoma.
Michael J. Keating has included themes like Cancer research, microRNA and Minimal residual disease in his Chronic lymphocytic leukemia study. He has researched Gastroenterology in several fields, including Refractory, Chronic myelogenous leukemia, Toxicity, Acute lymphocytic leukemia and Acute leukemia. Michael J. Keating interconnects Cytotoxic T cell and Glutathione in the investigation of issues within Immunology.
His primary areas of study are Internal medicine, Chronic lymphocytic leukemia, Immunology, Leukemia and Gastroenterology. His Internal medicine study combines topics from a wide range of disciplines, such as Surgery and Oncology. His Chronic lymphocytic leukemia research is multidisciplinary, incorporating perspectives in Cancer, Cancer research and Pathology.
His Immunology research focuses on Myeloid leukemia in particular. His Leukemia study integrates concerns from other disciplines, such as Lymphoma, Bone marrow and Pharmacology. Michael J. Keating combines subjects such as Phases of clinical research, Cytarabine, Regimen, Neutropenia and Acute lymphocytic leukemia with his study of Gastroenterology.
His primary scientific interests are in Chronic lymphocytic leukemia, Internal medicine, Ibrutinib, Cancer research and Oncology. A component of his Chronic lymphocytic leukemia study involves Leukemia and Immunology. Michael J. Keating focuses mostly in the field of Internal medicine, narrowing it down to topics relating to Gastroenterology and, in certain cases, Phases of clinical research.
His research in Ibrutinib intersects with topics in Discontinuation, Obinutuzumab, Venetoclax, Pharmacology and Bruton's tyrosine kinase. His Cancer research research integrates issues from Apoptosis, STAT3, breakpoint cluster region and Bone marrow. His research investigates the connection between Oncology and topics such as Clinical trial that intersect with problems in Adverse effect.
Michael J. Keating focuses on Chronic lymphocytic leukemia, Internal medicine, Ibrutinib, Leukemia and Cancer research. His Chronic lymphocytic leukemia research is within the category of Immunology. His Internal medicine research is multidisciplinary, relying on both Surgery and Oncology.
His research integrates issues of Venetoclax, Tyrosine kinase, Bruton's tyrosine kinase and Pharmacology in his study of Ibrutinib. The study incorporates disciplines such as Targeted therapy, Malignancy, Lipoprotein lipase and Intensive care medicine in addition to Leukemia. His Cancer research research focuses on STAT3 and how it connects with Chromatin immunoprecipitation.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia
George Adrian Calin;Calin Dan Dumitru;Masayoshi Shimizu;Roberta Bichi.
Proceedings of the National Academy of Sciences of the United States of America (2002)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
Michael Hallek;Bruce D. Cheson;Daniel Catovsky;Federico Caligaris-Cappio.
The New Regionalism in Western Europe: Territorial Restructuring and Political Change
Michael J. Keating.
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
Sergio Giralt;Elihu Estey;Maher Albitar;Koen Van Besien.
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
I F Khouri;M Keating;M Körbling;D Przepiorka.
Journal of Clinical Oncology (1998)
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
Michael J. Keating;Susan O'Brien;Maher Albitar;Susan Lerner.
Journal of Clinical Oncology (2005)
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.
Michael J. Keating;Ian Flinn;Vinay Jain;Jacques-Louis Binet.
ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia
Laura Z. Rassenti;Lang Huynh;Tracy L. Toy;Liguang Chen.
The New England Journal of Medicine (2004)
Nations Against the State: The New Politics of Nationalism in Quebec, Catalonia and Scotland
Michael James Keating.
Superoxide dismutase as a target for the selective killing of cancer cells
Peng Huang;Li Feng;Elizabeth A. Oldham;Michael J. Keating.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: